Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVAL: Ilofotase alfa for Sepsis-Associated AKI
NCT04411472Phase 3Terminated
- Sponsor
- AM-Pharma
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Replacement Enzymes
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in acute kidney injury (AKI) comparing Ilofotase Alfa with Placebo (2 arms). Primary endpoint: 28-day All-cause Mortality. Started Nov 2020; status: terminated.
02
Drugs
ilofotase alfa
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04411472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411472.